ReachMD CME

ReachMD
  • 4.3 (3)
  • SCIENCE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

  1. JAN 30

    Progress in Breast Cancer Care: Translating SABCS Data Into Practice

    CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/progress-in-breast-cancer-care-translating-sabcs-data-into-practice/48989/ This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participants will learn how to apply new evidence to expand therapeutic options, improve patient outcomes, and navigate emerging safety and quality of life considerations. =

    16 min

  2. JAN 23

    Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma

    CME credits: 0.25 Valid until: 23-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-line-moving-bispecific-antibodies-upstream-in-treating-multiple-myeloma/49265/ This expert lecture offers a focused review of the expanding role of bispecific antibodies earlier in the disease course of multiple myeloma. Learn about pivotal trial data with unprecedented efficacy that support this shift to use in early-line settings. Safety considerations, including infection risk and mitigation strategies, are addressed to guide real-world implementation. Together, these insights help clinicians optimize patient outcomes as bispecific antibodies move toward earlier integration in multiple myeloma care. On March 5, 2026, the FDA approved teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. =

    12 min

  3. JAN 15

    Interdisciplinary Strategies for BRCA-Mutated EBC: Testing, Targeting, and Team-Based Care

    CME credits: 1.00 Valid until: 15-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/interdisciplinary-strategies-for-brca-mutated-ebc-testing-targeting-and-team-based-care/36606/ This online educational activity, derived from a live Grand Rounds event, focuses on the application of molecular testing, evidence-based therapy selection, and interdisciplinary collaboration in the management of high-risk early-stage breast cancer (EBC) with germline BRCA mutations. In this chapterized activity, Dr. Jane Meisel reviews practical approaches for implementing guideline-directed BRCA testing and highlights disparities that impact equitable access to precision oncology. She also discusses the latest clinical evidence on adjuvant therapy for patients with high-risk EBC with germline BRCA mutations and uses a case-based learning lab to explore individualized adjuvant treatment strategies for these patients. The program also emphasizes proactive management of treatment-related adverse events, including patient counseling and coordinated supportive care, to optimize safety and adherence. Participants will gain practical strategies for integrating germline BRCA mutational status into treatment planning and for strengthening multidisciplinary care pathways, all in service of improving outcomes and reducing disparities for patients with high-risk EBC. =

    45 min

  4. JAN 5

    Addressing Unmet Needs in Metastatic Uveal Melanoma

    CME credits: 1.00 Valid until: 05-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/ Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bring these concepts to life, with special attention to application in VA and academic settings. Whether you're a medical oncologist, ocular oncologist, ophthalmologist, or APP, this discussion is designed to sharpen your skills and your care aligned with the latest science. =

    1 hr

  5. JAN 5

    Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence

    CME credits: 1.00 Valid until: 05-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/spotlight-on-systemic-sclerosis-pathophysiology-presentation-emerging-evidence/48716/ Systemic sclerosis (SSc) is complex and often diagnosed late. Explore the vasculopathy-fibrosis axis as a key driver of disease progression and clinical manifestations. Learn to recognize phenotypic red flags for ILD, PAH, and renal crisis, and apply risk stratification strategies to guide earlier intervention. Check out the evolving evidence on treatment selection and serious complications, emphasizing multidisciplinary care models and the role of patient-reported outcomes. =

    43 min

  6. JAN 2

    Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL

    CME credits: 1.00 Valid until: 02-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/asparaginase-based-treatment-young-adults-all/37193/ Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult protocols for young adults with ALL. However, many patients continue to be treated with adult protocols that lack asparaginase and are associated with poorer outcomes. In this dynamic, case-based activity, celebrity advocates Rob Benedict and Abbie Cobb, leading leukemia experts, and real people who have been treated for ALL explore practical foundations for successful asparaginase therapy. Leveraging new consensus recommendations, faculty experts explain how to select and when to switch asparaginase formulations, how to monitor serum asparaginase activity, and strategies to mitigate key toxicities while avoiding early asparaginase discontinuation that can compromise survival. Real-world stories from young adults who have been treated for ALL highlight the stakes of getting this right and the challenges of access, adherence, and comprehensive care that clinicians can address in everyday practice. Learning Goal/Purpose The goal of this educational activity is to enhance the knowledge, competence, and confidence that hematology/oncology healthcare providers need to achieve better outcomes for young adults with ALL through more consistent application of pediatric-inspired regimens, optimized …=

    55 min

  7. 12/31/2025

    Case Review: Can You Crack This IBD Case?

    CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

    7 min

  8. 12/31/2025

    Case Review: Targets Are Met—Can You Stick the Landing?

    CME credits: 1.00 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/ This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

    7 min
See All (362)

Ratings & Reviews

4.3
out of 5
3 Ratings

About

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Information

  • Creator
    ReachMD
  • Years Active
    2015 - 2026
  • Episodes
    362
  • Rating
    Clean
  • Copyright
    © Copyright 2026 ReachMD. All rights reserved.
  • Show Website
    ReachMD CME